Patents by Inventor Suryaprakash Sambhara

Suryaprakash Sambhara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250152696
    Abstract: An adenoviral vector with E1 and E3 regions removed and expressing the nucleoprotein or other immunogenic domain(s) of an influenza virus with or without the presence of the Autophagy-Inducing Peptide C5 (AIP-C5) from the CFP10 protein of Mycobacterium tuberculosis, compositions comprising same, and methods of use for general vaccination against heterosubtypic influenza viruses.
    Type: Application
    Filed: August 13, 2022
    Publication date: May 15, 2025
    Inventors: Suresh MITTAL, Suryaprakash SAMBHARA, Ekramy SAYEDAHMED, Chinnaswamy JAGANNATH
  • Publication number: 20220062357
    Abstract: The present disclosure provides method and composition for protection, prevention, and/or treatment against viral infections via activation of ILCs induced by certain virus, including but not limited to, influenza and/or non-replicating adenoviruses. The present disclosure further provides that activation of ILCs is an intervention strategy against not only influenza viral infectious epidemic and/or pandemic before a strain-matched vaccine is available but also against other viruses for which prophylactic vaccines may not be available.
    Type: Application
    Filed: August 24, 2021
    Publication date: March 3, 2022
    Applicants: Purdue Research Foundation, The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Mittal Suresh, Suryaprakash Sambhara, Weiping Cao, Wadzanai Mboko, Ekramy Sayedahmed
  • Patent number: 8163545
    Abstract: The present disclosure provides compositions and methods for eliciting an immune response against avian or pandemic influenza. The compositions include adenovirus vectors comprising avian influenza antigens, recombinant adenovirus and immunogenic compositions comprising such recombinant vectors and adenovirus. Methods for eliciting an immune response against avian or pandemic influenza involving administering such adenovirus vectors or recombinant adenovirus are also provided.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: April 24, 2012
    Assignees: United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Purdue Research Foundation
    Inventors: Suryaprakash Sambhara, Jacqueline Katz, Mary Hoelscher, Suresh K. Mittal, Dinesh S. Bangari
  • Publication number: 20120009130
    Abstract: The present disclosure provides compositions and methods of enhancing resistance to viral infections through targeted delivery of 5?PPP negative stranded siRNA via nanoparticles, specifically gold nanorods. The 5?PPP activates type I interferon through the signaling cascade providing a novel therapeutic and prophylactic for seasonal and pandemic influenza. The technology described herein also extends the findings to the use of nanoparticles for delivery of genetic material including but not limited to siRNA and microRNA to accomplish targeted nanoparticle based gene therapy.
    Type: Application
    Filed: May 6, 2011
    Publication date: January 12, 2012
    Applicant: NANOAXIS
    Inventors: Krishnan Chakravarthy, Suryaprakash Sambhara, Paul Knight
  • Publication number: 20100158939
    Abstract: The present disclosure provides compositions and methods for eliciting an immune response against avian or pandemic influenza. The compositions include adenovirus vectors comprising avian influenza antigens, recombinant adenovirus and immunogenic compositions comprising such recombinant vectors and adenovirus. Methods for eliciting an immune response against avian or pandemic influenza involving administering such adenovirus vectors or recombinant adenovirus are also provided.
    Type: Application
    Filed: December 23, 2009
    Publication date: June 24, 2010
    Inventors: Suryaprakash Sambhara, Jacqueline Katz, Mary Hoelscher, Suresh K. Mittal, Dinesh S. Bangari
  • Publication number: 20100099745
    Abstract: The present disclosure provides compositions and methods for enhancing resistance to viral infections. The compositions include adenovirus vectors containing nucleic acid molecules encoding CARD domains from RIG-I and MDA5, recombinant adenoviruses and immunogenic compositions comprising such recombinant adenovirus vectors and adenoviruses. Methods for enhancing resistance to viral infections involving administering such adenovirus vectors or recombinant adenovirus are also provided.
    Type: Application
    Filed: October 16, 2007
    Publication date: April 22, 2010
    Inventors: Suryaprakash Sambhara, Zha Guo
  • Publication number: 20080248057
    Abstract: Immunogenic compositions for administration to adults particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV and an immunoeffective amount of a non-virulent influenza virus preparation. The components of the composition when formulated as a vaccine for in vivo administration do not impair the immunogenicity of each other. The immunogenic composition may also contain an adjuvant.
    Type: Application
    Filed: May 21, 2008
    Publication date: October 9, 2008
    Inventors: George A. Cates, Suryaprakash Sambhara, David Burt, Michel H. Klein
  • Publication number: 20080187557
    Abstract: The present disclosure provides compositions and methods for eliciting an immune response against avian or pandemic influenza. The compositions include adenovirus vectors comprising avian influenza antigens, recombinant adenovirus and immunogenic compositions comprising such recombinant vectors and adenovirus. Methods for eliciting an immune response against avian or pandemic influenza involving administering such adenovirus vectors or recombinant adenovirus are also provided.
    Type: Application
    Filed: April 10, 2006
    Publication date: August 7, 2008
    Inventors: Suryaprakash Sambhara, Jacqueline Katz, Mary Hoelscher, Suresh K. Mittal, Dinesh S. Bangari
  • Patent number: 7169395
    Abstract: Immunogenic compositions for administration to adults, particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and by influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV and an immunoeffective amount of a non-virulent influenza virus preparation. The components of the composition, when formulated as a vaccine for in vivo administration, do not impair the immunogenicity of each other. The immunogenic composition may also contain an adjuvant.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: January 30, 2007
    Assignee: Sanofi Pasteur Limited
    Inventors: George A. Cates, Suryaprakash Sambhara, David Burt, Michel H. Klein
  • Publication number: 20060159700
    Abstract: Immunogenic compositions for administration to adults particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV and an immunoeffective amount of a non-virulent influenza virus preparation. The components of the composition when formulated as a vaccine for in vivo administration do not impair the immunogenicity of each other. The immunogenic composition may also contain an adjuvant.
    Type: Application
    Filed: September 17, 2003
    Publication date: July 20, 2006
    Inventors: George Cates, Suryaprakash Sambhara, David Burt, Michel Klein
  • Patent number: 6677127
    Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.
    Type: Grant
    Filed: September 13, 1999
    Date of Patent: January 13, 2004
    Assignee: Aventis Pasteur Limited
    Inventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
  • Patent number: 6641816
    Abstract: The invention relates to a method for enhancing the specific immune response against an immunogenic compound which comprises administering the immunogenic compound together with a poxvirus recombinant and a vaccinal antigen, which is not a poxvirus. The immunological material may be any biological material useful as a vaccine e.g., a polypeptide characteristic of a pathogenic microorganism or associated with a tumoral disorder, a DNA plasmid encoding a peptide or a polypeptide characteristic of a pathogenic microorganism or a tumor-associated antigen, or an hapten coupled to a carrier molecule. The poxvirus may be a live, attenuated or inactivated virus or a recombinant virus. Recombinant virus may encode a heterologous polypeptide such as chemokines, cytokines or co-immunostimulatory molecules or an homologous polypeptide, which is immunologically cross reactive with the immunogenic polypeptide or peptide.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: November 4, 2003
    Assignee: Aventis Pasteur S.A.
    Inventors: Michel Chevalier, Bernard Meignier, Catherine Moste, Suryaprakash Sambhara
  • Patent number: 6486135
    Abstract: Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: November 26, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
  • Patent number: 6083925
    Abstract: Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.
    Type: Grant
    Filed: March 5, 1999
    Date of Patent: July 4, 2000
    Assignee: Connaught Laboratories Limited
    Inventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
  • Patent number: 6022864
    Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein enclosing sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: February 8, 2000
    Assignee: Connaught Laboratories Limited
    Inventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
  • Patent number: 6017897
    Abstract: Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.
    Type: Grant
    Filed: July 18, 1997
    Date of Patent: January 25, 2000
    Assignee: Pasteur Merieux Connaught Canada
    Inventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
  • Patent number: 5843913
    Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: December 1, 1998
    Assignee: Connaught Laboratories Limited
    Inventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein